🇺🇸 FDA
Patent

US 11351161

Use of CDK9 inhibitors to reduce cartilage degradation

granted A61KA61K31/453A61K31/713

Quick answer

US patent 11351161 (Use of CDK9 inhibitors to reduce cartilage degradation) held by The Regents of the University of California expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/453, A61K31/713, A61K9/0019, A61P